Athira’s alternative Alzheimer’s approach runs into a PhII brick wall

Max Gelman

Senior Editor

Athira Pharma reported another setback Wednesday as its mid-stage Alzheimer’s study failed, becoming the latest biotech to come up short in the disease.

The Seattle …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Athira’s alternative Alzheimer’s approach runs into a PhII brick wall

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Athi­ra’s al­ter­na­tive Alzheimer’s ap­proach runs in­to a PhII brick wall

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Athira’s alternative Alzheimer’s approach runs into a PhII brick wall

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration